<DOC>
	<DOCNO>NCT00315484</DOCNO>
	<brief_summary>The purpose study compare hemoglobin ( Hgb ) response rate epoetin alfa ( PROCRIT ; 40,000 Units ( U ) SC weekly ) darbepoetin alfa ( ARANESP ; 200 mcg every week ) anemic cancer patient receive chemotherapy .</brief_summary>
	<brief_title>Hematologic Response Epoetin Alfa ( PROCRIT ) Versus Darbepoetin Alfa ( ARANESP ) Chemotherapy Induced Anemia</brief_title>
	<detailed_description>Chemotherapy relate anemia occurs majority cancer patient cause impaired treatment outcome , increase treatment-related complication alter quality life . Epoetin alfa administer weekly dosing schedule 40,000 Units subcutaneously ( [ SC ] , skin ) dose adjustment base hematologic response produce significant improvement hemoglobin level , decrease transfusion frequency improve quality life . It unknown recently develop agent , darbepoetin alfa , administer every week fix dose produce similar improvement hematologic quality life outcome . Thus , randomization study warrant utilizing weekly dosing ( QW ) Epoetin alfa compare every week ( Q2W ) darbepoetin alfa . Patients receive study medication 16 weeks.Safety &amp; efficacy evaluation perform specify interval throughout study.The study hypothesis Week 5 hemoglobin response rate Epoetin alfa group well Darbepoetin alfa group . The start dose study drug either Epoetin alfa ( PROCRIT ) 40,000 Units SC QW Darbepoetin alfa ( ARANESP ) 200 mcg SC Q2W . Doses may adjust depend patient 's hemoglobin level maximum 60,000 IU SC QW Epoetin alfa 300 mcg SC Q2W Darbepoetin alfa .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Histologically confirm diagnosis solid tumor malignancy Baseline hemoglobin value &lt; 11 g/dL Scheduled receive cyclic chemotherapy minimum 12 week &lt; 2 prior chemotherapy regimen metastatic set Adequate hematologic &amp; renal function platelet count &gt; 100,000/mm3 Estimated life expectancy &gt; 6 month Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 2 History stem cell bone marrow transplant Anemia due factor cancer/chemotherapy Prior treatment epoetin alfa darbepoetin alfa investigational form erythropoietin within previous 3 month Significant , uncontrolled disease/dysfunction pulmonary , cardiovascular , endocrine , neurologic , gastrointestinal , genitourinary system attributable underlying malignancy chemotherapy Uncontrolled hypertension recent history ( within 6 month ) uncontrolled cardiac arrhythmia , pulmonary embolism , thrombosis new onset seizure history second active malignancy Major infection require hospitalization antibiotic within 14 day randomization Transfusion white blood cell pack red blood cell within 28 day randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Anemia</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>hemoglobin level</keyword>
	<keyword>recombinant human erythropoietin</keyword>
	<keyword>epoetin alfa</keyword>
	<keyword>darbepoetin alfa</keyword>
</DOC>